Following Europe-wide discussions, the product information for Concerta was revised in November 2006, to advise about serious cardiovascular adverse effects, and to recommend that methylphenidate should not be used in children or adolescents with known serious structural cardiac abnormalities. The product information for Ritalin was revised accordingly in June 2007, and the Medicines and Healthcare products Regulatory Agency is currently in discussion with the licence holder for Equasym.
Copies of the most up-to-date product information for Ritalin, Concerta and Equasym can be found in the Electronic Medicines Compendium available at www.medicines.org.uk. This includes the patient information leaflet provided for patients with their medicines and summaries of product characteristics which provide information for doctors and pharmacists.